New Report Offering Insightful Analysis on Lampalizumab-Launch - 2017

 Over the years, various affective drugs have come up for preventing neovascular age-related macular degeneration (nAMD). However, medical researchers and pharmaceutical companies are yet to achieve any significant success in finding an effective treatment for geographic atrophy (GA), which is the late-stage atrophic form of dry age-related macular degeneration (dAMD). This is where lampalizumab becomes an exciting prospect, as it shows promising signs of becoming the first drug treatment for dAMD condition. Market Research Hub (MRH) has recently announced the inclusion of a new report in its vast internet database titled “Lampalizumab-Launch Insights, Market Research Reports 2017”. This report offers a well outlined background information on lampalizumab-launch

Request free Sample Report:- http://www.marketresearchhub.com/enquiry.php?type=S&repid=1309663

There has been a genuine concern over the growing prevalence of dAMD, especially in individuals with over 50 years of age. The condition can lead to central vision loss in late stages owing to atrophy of photoreceptor cells that are present in the central retina called macula. Hence, a comprehensive study has been conducted on the potential launch of Lampalizumab. The report comprise of information on all the major indication for which the drug is being developed along with the competitive landscape in the respective class.

In the report, the reader will also gain access to important patent details, forecast on product’s post launch market position and sales projections till 2022.  Lampalizumab is being developed by Genetech and Roche. It is a monoclonal antibody fragment that restricts complement factor D (CFD). Lampalizumab disrupts the activation of the alternative complement pathway by binding to CFD, which effectively controls the progression of dAMD condition.

The report will enable investors to get a clear picture of the potential launch of lampalizumab and its implications on the market. Further, the report talks about how Lampalizumab will perform in the market as well as a comparative analysis with other market contenders (both in pipeline and marketed). The report also covers subjects such as clinical trials that are being or have already been conducted for the drug. The in-house team of industry experts have analyzed various aspects of the market in relation with the upcoming launch of lampalizumab. In addition, the report provides a scoring of the drug that is currently in its III phase of developmental stage by scrutinizing data form all the important clinical trials for the product.

Furthermore, one-on-one comparison with other marketed products if available is carried out thoroughly. Analysis of other market contenders wither regards to the products also helps in determining its exact position in the space. This report is compiled using information and data sourced from primary and secondary resources as well as proprietary database. Secondary data and resources have been gathered from a range of non-printable and printable material such as news websites, search engines, trade journals, government websites, trade association, magazines, industry portals, books and industry associations.

Browse Full Report With TOC: http://www.marketresearchhub.com/report/lampalizumab-launch-insights-2017-report.html

For the scope of the research, the report also provides detailed product description along with its molecule type, mechanism of action and chemical properties. In addition, report also presents information on clinical and non-clinical studies for all the indications.

Enquire About this Report: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1312615

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of reports and analysis. MRH’s expansive collection of pharmaceutical market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,

Albany, NY 12207,

United States

Toll Free: 800-998-4852 (US-Canada)

Email: press@marketresearchhub.com

Website: http://www.marketresearchhub.com/

Read Industry News at - https://www.industrynewsanalysis.com/

This release was published on openPR.